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Risk of infections in patients with 
gout: a population-based cohort 
study
B. Spaetgens1,2,3, F. de Vries1,3,4, J. H. M. Driessen1,3,4, H. G. Leufkens1, P. C. Souverein1, 
A. Boonen2,3, J. W. M. van der Meer5 & L. A. B. Joosten5
To investigate the risk of various types of infections (pneumonia and urinary tract infection (UTI)), 
and infection-related mortality in patients with gout compared with population-based controls. A 
retrospective cohort study was conducted using data from the UK Clinical Practice Research Datalink 
(CPRD). All patients with a first diagnosis of gout and aged >40 years between January 1987-July 2014, 
were included and matched with up to two controls. Time-varying Cox proportional hazards models 
were used to estimate the risk of infections and mortality. 131,565 patients and 252,763 controls 
(mean age: 64 years, 74% males, mean follow-up of 6.7 years) were included in the full cohort. After 
full statistical adjustment, the risk of pneumonia was increased (adj. HR 1.27, 95% CI 1.18 to 1.36), 
while the risk of UTI (adj. HR 0.99, 95% CI 0.97 to 1.01) was similar in patients compared to controls. 
No differences between patients and controls were observed for infection-related mortality due to 
pneumonia (adj. HR 1.03, 95% CI 0.93 to 1.14) or UTI (adj. HR 1.16, 95% CI 0.98 to 1.37). In conclusion, 
patients with gout did not have decreased risks of pneumonia, UTI or infection-related mortality 
compared to population-based controls.
Gout is worldwide the most common type of inflammatory arthritis with estimates of prevalence ranging from 
2.5% in Europe to 3.9% in the United States1–3. It is a chronic disease with different disease manifestations varying 
from acute self-limiting attacks to chronic tophaceous gout4. Gout and the accompanying hyperuricaemia have 
also been associated with a large number of comorbidities, such as cardiovascular disease, hypertension, diabetes 
and chronic kidney disease, although it remains unclear whether there is a causal relation with these comorbid-
ities5, 6.
The pathogenesis of gout is well understood, with a major role for monosodium urate (MSU) crysals which 
are formed during a state of hyperuricaemia7. In the joints these MSU crystals elicit an inflammatory response by 
activation of the NLRP3 inflammasome, which eventually leads to production of the pro-inflammatory cytokine 
interleukin (IL)-1bèta8–10. Also, in patients with tophaceous gout, it has been shown that pro-inflammatory 
cytokines such als IL-1bèta are expressed in the tophus, suggesting a state of chronic inflammation induced and/
or stimulated by MSU crystals11. Isolated peripheral blood mononuclear cells (PBMCs) of patients with gout 
produce more IL-1bèta when stimulated with MSU, when compared to blood cells of healthy controls12. Further, 
MSU seems to enhance the function of these PBMCs by epigenetic mechanisms resulting in increased cytokine 
production (‘Trained Immunity’)13. Recent evidence further revealed that the production of IL-1bèta and IL-6 
were higher in patients with gout, and serum concentrations correlated with serum uric acid (sUA)14.
As such, the net result of aforementioned pathways suggest a pro-inflammatory state in patients with hyper-
uricaemia and/or gout14.
The presence of a pro-inflammatory state related to hyperuricaemia has led to the hypothesis that patients 
with gout may have an enhanced resistance to infections, because previous research indicated that IL-1bèta aug-
ments the quality of host defence against bacteria and viruses15. However, the clinical correlate of this concept 
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has never been explored. Since gout is classically treated with colchicine for acute flares, and with allopurinol 
for long-term uric acid lowering treatment (ULT), it is important to consider a potential effect of these drugs 
on the relation between gout and infections. As such, we hypothesized that (I) patients with gout acquire 
fewer community-acquired infections (e.g., pneumonia, urinary tract infection (UTI)) and encounter a lower 
infection-related mortality rate, (II) treatment with colchicine enhances infections, because of its immunosup-
pressive effects, and (III) treatment with allopurinol neutralizes the protective role of high sUA levels of infections.
In view of the above, the objective of this study was to investigate the risk of various types of infections (pneu-
monia and UTI), and infection-related mortality in patients with gout compared with population-based controls 
without gout.
Patients and Methods
Design and data source. A retrospective cohort study was conducted using data from the British Clinical 
Practice Research Datalink (CPRD) GOLD (January 1987–July 2014). CPRD is formerly known as the General 
Practice Research Database (GPRD) and contains the computerized medical records of approximately 13 million 
patients under care of general practitioners in the United Kingdom (UK) who are representative for 6.9% of the 
total UK population. Practices contribute to CPRD, only when their data quality is up to research standards. Since 
1987, data recorded in the CPRD include demographic information, prescription details, lifestyle parameters, 
clinical events, preventive care provided and specialist referrals. CPRD has been extensively validated16, and used 
previously to study gout17, and infections including pneumonia18. About 75% of all practices in England (58% 
of all UK CPRD practices) were linked to data of the Office of National Statistics (ONS) (January 1998–January 
2012)19. The ONS provided data for the causes of death and the exact date as recorded on death certificates by a 
medical doctor. Linkage of death certificates to CPRD has a high level of validity20.
Ethical approval
CPRD has been granted Multiple Research Ethics Committee approval (05/MRE04/87) to undertake purely 
observational studies with external data linkages, including ONS mortality data. The present study is based 
on anonymised and unidentifiable CPRD data and is also approved by the Independent Scientific Advisory 
Committee (ISAC) of the Medicine and Healthcare products Regulatory Agency (protocol number 14_123R), 
which is primarily responsible for reviewing the study protocols. In the case of this observational research no 
further ethical approval deemed necessary by ISAC.
Study population. All patients with a first diagnosis of gout during the period of valid data collection (from 
1 January 1987 to 30 June 2014) and aged above 40 years during the period of valid CPRD data collection were 
included. Each patient with gout was matched by year of birth, sex, and practice to up to two patients without a 
diagnosis of gout using incidence density sampling. The date of the first recorded diagnosis of gout defined the 
index date and controls were assigned the same index date as their matched patient with gout. Patients or controls 
with a history of exposure to colchicine and ULT (allopurinol, febuxostat and/or uricosuric drugs) before index 
date were excluded.
When the outcome infection-related mortality was evaluated, data were restricted to the participants with 
linkage to ONS data. For this analysis, the period of valid data collection was restricted from 1 January 1998 to 
31 December 2011.
Study outcome(s) and covariates. The primary outcomes of interest were a first event of pneumonia 
(specified by read codes) or UTI (specified by read codes or prescriptions for nitrofurantoin or trimethoprim, 
since in the UK nitrofurantoin is exclusively, and trimethoprim in 95% of all cases prescribed for the treat-
ment of UTI). The secondary outcome of interest was infection-related mortality (death related to pneumonia 
[International Classification of Diseases, Tenth Revision (ICD-10) codes: J10.0-J18.9] or UTI [ICD-10 codes: 
N39.0]).
Potential confounders assessed at baseline included sex, body mass index (BMI), smoking status and alcohol 
use. Age and an estimated glomerular filtration rate (eGFR) were included as time-dependent variables at the 
start of each (30-day) time interval. When pneumonia or infection-related mortality due to pneumonia was the 
outcome, potential confounders included a history of pneumonia (more than 3 months ago), a history of sinus-
itis, influenza infection, stroke, lung cancer, chronic obstructive pulmonary disease (COPD), acute bronchitis, 
asthma, diabetes, dementia, epilepsy/seizures, dysphagia, HIV/AIDS and the use of the following medications 
within the previous 6 months: antipsychotics, acid suppressants, bronchodilators/inhaled corticosteroids, anti-
convulsants, immunosuppressants or systemic glucocorticoids and within 1 year prior: an influenza vaccination, 
and within 5 year prior: a pneumococcal vaccination. When UTI or infection-related mortality due to UTI were 
the outcome, potential confounders included a history of diabetes, malignancies excluding non-melanoma skin 
cancer, HIV/AIDS, recent use (within the previous 3 months) of urinary catheters, and the use of immunosup-
pressants or systemic glucocorticoids in the 6 months before. All confounders but age were treated as categorical 
variables.
Statistical Analysis. Analyses were conducted using time-varying Cox proportional hazard models to esti-
mate the risk of each outcome with exposure to gout. Patients were followed from the index date up to the end 
of data collection, the outcome of interest, the date of transfer out of the practice area or death, whichever came 
first. Follow-up was stratified into periods of 30 days. Potential confounders were included in the final model if 
they independently changed the bèta-coefficient of the univariate analysis by ≥5%, or when consensus (within 
the research team) about inclusion was reached, supported by scientific evidence. Analyses were repeated after 
stratification for treatment (current (<31 days), recent (31–91 days), past (>91 days) users) with allopurinol or 
colchicine. Data management and statistical analyses were conducted using SAS 9.3 (PHREG procedure).
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Results
In total, 162,181 patients with gout and 323,988 controls aged 40+ years were identified. Next, 30,284 gout 
patients and 15,400 controls with a prescription of colchicine or ULT before index date were excluded, and a 
remaining 56,105 subjects who were no longer matched. As a result, 131,565 patients with gout were included 
along with 252,763 controls without gout (mean age: 64 years, 74% males) with a mean follow-up of 6.7 years for 
both patients and controls in our full cohort. When infection-related mortality was the outcome 69,987 patients 
and 134,549 controls for whom death-certificate data were available for analyses after linkage to the ONS (Fig. 1) 
were included.
Baseline characteristics of patients with gout and controls in both cohorts are shown in Table 1. Patients with 
gout had, compared to controls, a higher BMI, more often an eGFR below 60 mL/min/1.73, consumed more often 
alcohol, suffered more frequently of asthma and/or COPD, diabetes, ischemic heart disease and atrial fibrillation. 
Furthermore, patients with gout were more likely users of systemic glucocorticoids or bronchodilators. No differ-
ences were observed for a history of malignancies, HIV or use of urinary catheters or immunosuppressant drugs.
Table 2 shows that gout was associated with a 34% increased risk of pneumonia, after adjustment for age and 
sex (HR 1.34, 95% CI 1.25 to 1.43). Full statistical adjustment led to a marginal reduction in the risk estimate 
(adjusted (adj.) HR 1.27, 95% CI 1.18 to 1.36). Further stratification by use of gout medication showed that there 
was no increased risk of pneumonia with current colchicine use (adj. HR 0.88, 95% CI 0.54 to 1.44), while recent 
and past use was associated with a doubled pneumonia risk. Current exposure to allopurinol was associated with 
an increased risk of pneumonia (adj. HR 1.41, 95% CI 1.23 to 1.61), which was similar compared to the risk of 
non-allopurinol use. Discontinuation of allopurinol barely altered the risk of pneumonia.
Figure 1. Flowchart of the study subjects.
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Characteristics
Full Cohort Cohort linked with ONS
Gout patients n = 131,565 Controls n = 252,763 Gout patients n = 69,987 Controls n = 134,549
Mean follow-up time, years (SD) 6.7 (5.1) 6.7 (5.1) 7.3 (4.9) 7.2 (5.0)
Number of men 97,179 (73.9) 186,021 (73.6) 52,024 (74.3) 99,612 (74.0)
Age
Mean age at index date, years (SD) 64 (13.5) 64 (13.5) 64 (13.5) 64 (13.5)
 40–49 years 23,304 (17.7) 46,032 (18.2) 12,474 (17.8) 24,607 (18.3)
 50–59 years 27,968 (21.3) 54,730 (21.7) 14,967 (21.4) 29,380 (21.8)
 60–69 years 31,262 (23.8) 59,875 (23.7) 16,614 (23.7) 31,896 (23.7)
 70 + years 49,031 (37.3) 92,126 (36.4) 25,932 (37.1) 48,666 (36.2)
BMI
Mean BMI at index date, kg/m2 (SD) 29 (5.2) 27 (4.8) 29 (5.2) 27 (4.8)
 <20.0 kg/m2 1,756 (1.3) 7,461 (3.0) 954 (1.4) 4,030 (3.0)
 20.0–24.9 kg/m2 21,146 (16.1) 63,823 (25.3) 11,624 (16.6) 35,430 (26.3)
 25.0–29.9 kg/m2 46,675 (35.5) 80,677 (31.9) 25,449 (36.4) 43,679 (32.5)
 30.0–34.9 kg/m2 25,308 (19.2) 30,167 (11.9) 13,510 (19.3) 15,747 (11.7)
 ≥35.0 kg/m2 12,107 (9.2) 10,909 (4.3) 6,143 (8.8) 5,609 (4.2)
 Missing 24,573 (18.7) 59,726 (23.6) 12,307 (17.6) 30,054 (22.3)
Smoking status
 Never 62,964 (47.9) 118,635 (46.9) 33,274 (47.5) 63,441 (47.2)
 Current 26,517 (20.2) 60,059 (23.8) 14,715 (21.0) 32,704 (24.3)
 Ex 38,941 (29.6) 60,101 (23.8) 20,961 (29.9) 32,625 (24.2)
 Missing 3,143 (2.4) 13,968 (5.5) 1,037 (1.5) 5,779 (4.3)
Alcohol use
 No 18,772 (14.3) 40,138 (15.9) 9,473 (13.5) 20,179 (15.0)
 Yes 101,993 (77.5) 178,735 (70.7) 55,652 (79.5) 98,483 (73.2)
 Missing 10,800 (8.2) 33,890 (13.4) 4,862 (6.9) 15,887 (11.8)
eGFR most recent within previous year
 eGFR, ml/min/1.73 m2 (SD) 73 (22.7) 81 (22.0) 73 (22.7) 81 (22.0)
 >90 ml/min/1.73 m2 14,769 (11.2) 34,509 (13.7) 7,456 (10.7) 17,412 (12.9)
 60–89 ml/min/1.73 m2 38,052 (28.9) 63,485 (25.1) 21,267 (30.4) 35,780 (26.6)
 30–59 ml/min/1.73 m2 19,251 (14.6) 16,428 (6.5) 10,771 (15.4) 9,306 (6.9)
 15–29 ml/min/1.73 m2 1,609 (1.2) 878 (0.3) 889 (1.3) 499 (0.4)
 <15 ml/min/1.73 m2 183 (0.1) 186 (0.1) 106 (0.2) 106 (0.1)
 Missing 57,701 (43.9) 137,277 (54.3) 29,498 (42.1) 71,446 (53.1)
History of comorbidities
 Pneumonia 3,280 (2.5) 4,801 (1.9) 1,735 (2.5) 2,653 (2.0)
 UTI 13,010 (9.9) 21,979 (8.7) 6,828 (9.8) 11,599 (8.6)
 HIV 70 (0.1) 156 (0.1) 18 (0.0) 59 (0.0)
 Lung cancer 207 (0.2) 460 (0.2) 103 (0.1) 224 (0.2)
 Malignanciesb 14,363 (10.9) 25,684 (10.2) 7,729 (11.0) 13,706 (10.2)
 Asthma/COPD 18,829 (14.3) 29,940 (11.8) 9,903 (14.1) 15,852 (11.8)
 Sinusitis 14,754 (11.2) 26,043 (10.3) 7,920 (11.3) 14,181 (10.5)
 Diabetes 11,151 (8.5) 16,952 (6.7) 5,872 (8.4) 8,731 (6.5)
 Dementia 985 (0.7) 3,071 (1.2) 448 (0.6) 1,472 (1.1)
 Epilepsy 2,143 (1.6) 4,523 (1.8) 1,091 (1.6) 2,333 (1.7)
 Dysphagia 2,371 (1.8) 4,169 (1.6) 1,248 (1.8) 2,259 (1.7)
 Ischaemic heart disease 19,492 (14.8) 24,177 (9.6) 10,132 (14.5) 12,651 (9.4)
 Atrial fibrillation/flutter 11,544 (8.8) 10,972 (4.3) 6,016 (8.6) 5,848 (4.3)
 Stroke 7,681 (5.8) 11,457 (4.5) 3,888 (5.6) 5,908 (4.4)
Drug use within six months before
 Bronchodilators 14,423 (11.0) 21,495 (8.5) 7,426 (10.6) 11,128 (8.3)
 Inhaled corticosteroids 7,052 (5.4) 10,902 (4.3) 3,811 (5.4) 5,989 (4.5)
 Antipsychotics 1,252 (1.0) 3,602 (1.4) 630 (0.9) 1,878 (1.4)
 Anticonvulsants 2,785 (2.1) 5,671 (2.2) 1,367 (2.0) 2,894 (2.2)
 Systemic corticosteroids 5,538 (4.2) 7,915 (3.1) 2,908 (4.2) 4,177 (3.1)
 Immunosuppressants 835 (0.6) 1,549 (0.6) 465 (0.7) 798 (0.6)
 Influenza vaccination (1 year before) 48,379 (36.8) 80,038 (31.7) 28,345 (40.5) 48,188 (35.8)
 Pneumococcal vaccination (5 years before) 23,174 (17.6) 38,350 (15.2) 12,846 (18.4) 21,805 (16.2)
Table 1. Baseline characteristics of patients with gout and controls, separately for the full sample and the sample 
that could be linked to death certificate data from the Office of National Statistics (ONS)a. Abbreviations: SD, 
standard deviation; ONS, the Office of National Statistics; BMI, Body mass index; eGFR, estimated Glomerular 
Filtration Rate; HIV, Human Immunodeficiency Virus; COPD, Chronic Obstructive Pulmonary Disease. a) Data 
represent the number (%) of patients, unless stated otherwise. b) Excluding non-melanoma skin cancer.
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Table 3 shows that gout was associated with a 14% increased risk of UTI, after adjustment for age and sex (HR 
1.14, 95% CI 1.12 to 1.17). After full statistical adjustment this increased risk disappeared (adj. HR 0.99, 95% CI 
0.97 to 1.01). The following confounders were responsible for this shift: sex, a history of chronic kidney disease, 
No. of 
pneumonia 
events 
(n = 3,586)
Age/sex 
adjusted HR 
(95% CI)
Adjusted HRa 
(95% CI)
No Gout 2,048 Reference Reference
Gout 1,538 1.34 (1.25 to 1.43)
1.27 (1.18 to 
1.36)
By colchicine exposure
 Never use 1,159 1.24 (1.15 to 1.33)
1.22 (1.13 to 
1.31)
Current use 
(<31 days) 16
1.16 (0.71 to 
1.90)
0.88 (0.54 to 
1.44)
Recent use 
(31–91 days) 32
2.09 (1.48 to 
2.97)
1.60 (1.13 to 
2.27)
Past use (>91 
days ago) 331
1.80 (1.60 to 
2.02)
1.49 (1.32 to 
1.68)
By allopurinol exposure
Never use 954 1.22 (1.13 to 1.32)
1.18 (1.10 to 
1.28)
Current use 
(<31 days) 262
1.65 (1.45 to 
1.87)
1.41 (1.23 to 
1.61)
Recent use 
(31–91 days) 119
1.76 (1.46 to 
2.11)
1.58 (1.31 to 
1.91)
Past use (>91 
days ago) 203
1.43 (1.24 to 
1.65)
1.39 (1.21 to 
1.61)
Table 2. Risk of pneumonia in patients with gout compared to matched controls, stratified by use of colchicine 
and allopurinol. Abbreviations: HR: indicates hazards ratio; CI, confidence interval; PY, person years. (a) 
Adjusted for age, sex, body mass index, smoking status, alcohol use, the most recently recorded estimated 
glomerular filtration rate in the past year, a history of dementia, dysphagia, and the use of bronchodilators, 
inhalation corticosteroids, systemic corticosteroids, non-insulin anti-diabetic drugs, insulin within 6 months 
before, the use of influenza vaccinations 1 year before and the use of pneumococcal vaccinations 5 years before.
No. of UTI Events 
(n = 35,807)
Age/sex 
adjusted HR 
(95% CI)
Adjusted HRa 
(95% CI)
No Gout 22,719 Reference Reference
Gout 13,088 1.14 (1.12 to 1.17)
0.99 (0.97 to 
1.01)
By colchicine exposure
 Never use 10,596 1.11 (1.08 to 1.14)
0.97 (0.94 to 
1.01)
Current use 
(<31 days) 225
1.83 (1.62 to 
2.07)
1.42 (1.24 to 
1.64)
Recent use 
(31–91 days) 235
1.71 (1.52 to 
1.93)
1.29 (1.12 to 
1.49)
Past use (>91 
days ago) 2,032
1.27 (1.22 to 
1.33)
1.00 (0.95 to 
1.06)
By allopurinol exposure
Never use 9,256 1.15 (1.12 to 1.18)
1.01 (0.98 to 
1.05)
Current use 
(<31 days) 1,864
1.31 (1.26 to 
1.37)
1.05 (0.99 to 
1.12)
Recent use 
(31–91 days) 766
1.19 (1.11 to 
1.27)
1.04 (0.94 to 
1.14)
Past use (>91 
days ago) 1,202
0.90 (0.85 to 
0.95)
0.73 (0.67 to 
0.80)
Table 3. Risk of urinary tract infection (UTI) in patients with gout compared to matched controls, stratified 
by use of colchicine and allopurinol. Abbreviations: HR: indicates hazards ratio; CI, confidence interval; PY, 
person years. (a) Adjusted for age, sex, body mass index, smoking status, alcohol use, the most recently recorded 
estimated glomerular filtration rate in the past year, a history of cancer, stroke and the use of an urinary catheter, 
systemic corticosteroids, non-insulin antidiabetic drugs and insulin 6 months before.
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cancer, stroke, recent use of a urinary catheter and the use of systemic corticosteroids or anti-diabetics 6 months 
prior. Further stratification by the use of medication showed an increased risk of UTI with current and recent 
colchicine use (adj. HR 1.42, 95% CI 1.24 to 1.64 and adj. HR 1.29, 95% CI 1.12 to 1.49), whereas past colchicine 
use was not associated with an increased risk (adj. HR 1.00, 95% CI 0.95 to 1.06) compared to controls. Current 
and recent use of allopurinol was associated with a similar risk of UTI compared to controls (adj. HR 1.05, 95% CI 
0.99 to 1.12 and adj. HR 1.04, 95% CI 0.94 to 1.14, respectively). However, past use of allopurinol was associated 
with a 27% reduced risk of UTI (adj. HR 0.73, 95% CI 0.67 to 0.80).
Table 4 shows that there was no association between infection-related mortality due to pneumonia and expo-
sure to gout versus controls (adj. HR 1.03, 95% CI 0.93 to 1.14). Stratification by use of gout medication also did 
not alter the risk estimates.
Table 5 shows that no association between infection-related mortality due to UTI and exposure to gout versus 
controls was observed (adj. HR 1.16, 95% CI 0.98 to 1.37). Stratification by use of gout medication revealed that 
never use of colchicine (adj. HR 1.25, 95% CI 1.04 to 1.49) and recent allopurinol use (adj. HR 1.56, 95% CI 1.00 
to 2.43) were associated with an increased risk of mortality due to UTI.
Discussion
This study showed that the risk of pneumonia, UTI or infection-related mortality was not reduced in patients with 
gout compared to population-based controls. Moreover, stratification by treatment with colchicine did not iden-
tify subgroups with reduced risks for pneumonia, UTI or infection-related mortality either, while stratification 
by treatment with allopurinol only showed a decreased risk of UTI in past users. On the contrary, we found that 
patients with gout had an elevated risk of pneumonia. Therefore, the results of the present study were not in line 
with our main hypothesis that patients with gout would have a decreased risk of acquiring infections. In addition, 
our findings regarding our secondary hypotheses, i.e. that treatment with colchicine (because of its immunosup-
pressive effects) or allopurinol (because it reduces sUA and therefore neutralizes the protective role of sUA) might 
enhance infections were inconsistent.
To the best of our knowledge, this is the first study that evaluated the risk of community-acquired infections 
in patients with gout versus matched controls. A previous population-based study by Lim et al.21, investigated the 
risk of septic arthritis in patients with gout, and revealed that gout patients had a 2.6-fold increased risk of devel-
oping septic arthritis when compared to non-gouty controls. However, the protective effect of a pro-inflammatory 
state is unlikely to play a major role in the pathophysiology of septic arthritis in these patients. Local joint damage 
due to gout, and possibly arthrocentesis and intra-articular injections, but also misdiagnosis of the disease, since 
gout and septic arthritis have similar disease features, might have contributed to this increased risk. Our study 
also showed increased risks of infection in certain subgroups, although only for pneumonia this risk persisted 
No. of events 
(death) 
(n = 1,965)
Age/sex 
adjusted HR 
(95% CI)
Adjusted HRa 
(95% CI)
No Gout 1,390 Reference Reference
Gout 575 0.97 (0.88 to 1.07)
1.03 (0.93 to 
1.14)
By colchicine exposure
 Never use 475 0.99 (0.89 to 1.10)
1.07 (0.96 to 
1.19)
Current use 
(<31 days) <5 events
b 0.67 (0.25 to 
1.78)
0.65 (0.24 to 
1.74)
Recent use 
(31–91 days) <5 events
b 0.61 (0.27 to 
1.36)
0.61 (0.27 to 
1.37)
Past use (>91 
days ago) 92
0.92 (0.76 to 
1.12)
0.92 (0.75 to 
1.13)
By allopurinol exposure
Never use 384 0.98 (0.87 to 1.10)
1.06 (0.94 to 
1.19)
Current use 
(<31 days) 91
1.20 (0.97 to 
1.48)
1.22 (0.98 to 
1.52)
Recent use 
(31–91 days) 30
0.89 (0.63 to 
1.25)
0.95 (0.67 to 
1.33)
Past use (>91 
days ago) 70
0.93 (0.73 to 
1.18)
0.97 (0.76 to 
1.23)
Table 4. Risk of infection-related mortality due to pneumonia, in patients with gout compared to matched 
controls, stratified by use of colchicine and allopurinol. Abbreviations: HR: indicates hazards ratio; CI, 
confidence interval; PY, person years. (a) Adjusted for age, sex, body mass index, smoking status, alcohol 
use, the most recently recorded estimated glomerular filtration rate in the past year, a history of dementia, 
dysphagia, stroke, epilepsy, ischaemic heart disease, sepsis and the use of bronchodilators, inhalation 
corticosteroids, systemic corticosteroids, non-insulin anti-diabetic drugs and insulin within 6 months before, 
the use of influenza vaccinations 1 year before and the use of pneumococcal vaccinations 5 years before. (b) 
According to Independent Scientific Advisory Committee (ISAC) guidance on the content of protocols for 
research using CPRD data no cell containing <5 events are reported.
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after adjusting for classic confounders. The risk of UTI disappeared after statistically adjustment for confound-
ers (chronic kidney disease, systemic corticosteroids, use of anti-diabetics, sex and use of an urinary catheter). 
From a pathophysiological view, there is no good reason why gout itself should increase the risk of infections 
after adjusting for confounders. It is possible that a true inverse association may have not been detected due to 
a wide range of epidemiological limitations, such as misclassification bias, detection bias or residual confound-
ing. Although we were able to adjust for many possible confounders, it is likely residual confounding still has 
occurred. First, our data show that gout patients have a higher BMI, suffer more often from chronic kidney 
disease, asthma and/or COPD and diabetes, and were also more likely to use systemic glucocorticoids. Despite 
the fact we have adjusted for these confounders in our analysis, we acknowledge we were unable to correct for 
all potential confounders such as under-ascertained comorbidities and for the severity of health impact of some 
confounders, which occur more often in gout patients. Second, another concern is that glucocorticoids, which are 
well-known to increase the risk of infections, were prescribed more to gout patients. Although this was adjusted 
for, it may have introduced information bias, while exposure to glucocorticoids was measured, as for all drugs, 
from prescriptions. As such, we have no information whether these drugs were actually taken. Not taking these 
drugs (adherence is a well-known problem in gout patients) could have led to an underestimation of the true 
risk. Third, missing data with respect to smoking, BMI or eGFR might have introduced residual confounding as 
a result of imperfect adjustment of these variables.
Although our data do not support our hypothesis of a net pro-inflammatory state that enhances resistance to 
infections in patients with gout, it is too early to reject the hypothesis based on these data alone. Trained immu-
nity (or innate immune memory) is mediated by epigenetic reprogramming of monocytes and/or macrophages22. 
This reprogramming when induced by BCG is present for approximately 1 year23. However, it is possible that 
sUA-induced trained immunity is not so long lasting as was demonstrated for BCG or bèta-glucan24. It is also 
possible that the clinical protective effect of sUA is small or might be counteracted by other mechanisms (such as 
residual confounding, or the fact this is a population-based cohort in which sUA levels are not sharply increased).
The impact of treatment with allopurinol and colchicine was more difficult to explain due to inconsistent 
findings. It was interesting to see that especially past allopurinol use was associated with a decreased risk of UTI 
compared to controls. A possible explanation might be that the rise in sUA after discontinuation of allopurinol 
(non-compliance to allopurinol is well recognized25) is protective in acquiring infections, while in current and 
recent users allopurinol might neutralize the protective effect of sUA. With regard to pneumonia, never using 
allopurinol was associated with the lowest infection risks. These patients might have been exposed more consist-
ent to higher sUA levels over time, but still might have an increased risk when compared to controls due to resid-
ual confounding. For colchicine we hypothesized that it enhances infections because of its anti-inflammatory and 
immune-modulatory effects. Case-reports and case studies have shown that patients with colchicine overdose 
No. of events 
(death) (n = 697)
Age/sex 
adjusted HR 
(95% CI)
Adjusted HRa 
(95% CI)
No Gout 454 Reference Reference
Gout 243 1.19 (1.01 to 1.40)
1.16 (0.98 to 
1.37)
By colchicine exposure
 Never use 195 1.24 (1.04 to 1.48)
1.25 (1.04 to 
1.49)
 Current use 
(<31 days) <5 events
b 0.94 (0.23 to 
3.76)
0.75 (0.19 to 
3.02)
 Recent use 
(31–91 days) <5 events
b 1.48 (0.62 to 
3.60)
1.23 (0.51 to 
2.99)
 Past use (>91 
days ago) 42
1.12 (0.82 to 
1.52)
0.99 (0.72 to 
1.36)
By allopurinol exposure
 Never use 158 1.14 (0.95 to 1.37)
1.14 (0.94 to 
1.38)
 Current use 
(<31 days) 31
1.15 (0.79 to 
1.67)
1.03 (0.71 to 
1.51)
 Recent use 
(31–91 days) 20
1.62 (1.04 to 
2.52)
1.56 (1.00 to 
2.43)
 Past use (>91 
days ago) 34
1.27 (0.89 to 
1.82)
1.22 (0.85 to 
1.74)
Table 5. Risk of infection-related mortality due to UTI, in patients with gout compared to matched controls, 
stratified by use of colchicine and allopurinol. Abbreviations: HR: indicates hazards ratio; CI, confidence 
interval; PY, person years. (a) Adjusted for age, sex, body mass index, smoking status, alcohol use, the most 
recently recorded estimated glomerular filtration rate in the past year, a history of dementia, dysphagia, 
stroke, epilepsy, ischaemic heart disease, sepsis and the use of bronchodilators, inhalation corticosteroids, 
systemic corticosteroids, non-insulin anti-diabetic drugs and insulin within 6 months before. (b) According 
to Independent Scientific Advisory Committee (ISAC) guidance on the content of protocols for research using 
CPRD data no cell containing <5 events are reported.
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develop infectious complications26–28, also in the absence of neutropenia, a well-established side effect29. Also, 
in patients using normal doses of colchicine and with normal cell counts, inhibitory effects of colchicine on leu-
kocyte functions, such as degranulation30, chemotaxis and adherence31, might be present. However, it is of note 
that the use of colchicine for acute gout in the UK is limited. Moreover, the effects were not consistent with the 
expected direction. Finally, it cannot be excluded that patients with current colchicine use actually had an infec-
tion that triggered an acute attack/flare and therefore a prescription of colchicine.
Our hypothesis that patients with gout have a reduced risk of infection-related mortality, could not be con-
firmed. This finding is in line with findings from a study on mortality in patients with gout that had specified 
causes of death, other than cardiovascular death32. This retrospective cohort study that used the National Death 
Registry in Taiwan showed that women with gout had an excess mortality due to infectious diseases (standardized 
mortality ratio 2.25) compared to women without gout. However, this association disappeared after multivariate 
adjustment. Literature on mortality in patients with gout has shown that patients with gout have an increased risk 
of cardiovascular mortality, as well as all-cause mortality33. As such, it would be interesting to investigate whether 
patients with gout, who had acquired an infection might die because of cardiovascular causes rather than due to 
infections. Not in the least, because it is known that infections might exacerbate underlying cardiovascular dis-
ease34. This was however beyond the scope of this study.
Our study has several strengths. It has a large sample size, used general population data and had a follow-up. 
The large amount clinical information routinely and longitudinally collected in clinical practice, allowed us to 
statistically adjust for many potential confounders such as, age, sex, smoking status, alcohol use, comorbidity and 
use of medication.
Our study has other limitations that need to be addressed. First, sUA levels, which play a key role in our 
hypothesis, are not routinely collected in CPRD. Patients with gout therefore acted as a surrogate representing the 
status of hyperuricaemia. Second, the use of diagnostic codes, mainly registered by general practitioners rather 
than rheumatologists, to define gout might have resulted in non-differential misclassification of the outcome and 
a bias towards null. Still, gout, but also the outcomes (pneumonia, UTI and mortality) are already extensively 
studied in CPRD and studies performed with CPRD have been extensively validated16, 35.
Third, diagnostic bias may have masked a protective effect of gout on infections, because patients with gout 
may more often visit their general practitioner compared to controls. This may have increased their likelihood to 
be diagnosed with a pneumonia or UTI.
In conclusion, this study did not support the hypothesis that patients with gout may acquire fewer 
community-acquired infections, such as pneumonia and UTI or have lower infection-related mortality. In con-
trast, this study showed that patients with gout had an increased risk of pneumonia and UTI, although for the lat-
ter these increased risks were attributable to classic risk factors. Therefore, the clinical relevance of these findings 
remain unclear and the effects seem small. Future research is needed to elucidate the exact mechanisms between 
uric acid, interleukins, infections and the role of colchicine and allopurinol.
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